Related to ScinoPharm Invests $37.6M to Construct Injectable Cancer Drugs Plant

• Serametrix Allies with Ludwig Institute to Exploit Tumor Antigens as Biomarkers
  
• BioTime Sets Up Subsidiary to Develop hESC-Based Therapies for Cancer
  
• Novavax Taps Xcellerex to Bolster Flu Vaccine Production
  
• Alnara Selects Lonza for Commercial Manufacture of Pancreatic Insufficiency Therapy
  
• Lonza Takes Equity Stake in Ciliate-Expression System Company
  
• Genetic Tech to Distribute Rosetta’s Cancer Tests in Australia, New Zealand, and Singapore
  
• ArmaGen Chooses PacificGMP to Manufacture Fusion Protein for Phase I Trial in Stroke and Parkinson’s
  
• GE and Lilly Develop Prototype to Visualize and Map Cancer Biomarker Networks
  
• GSK to Exploit SuperGen’s Epigenetics Expertise in Cancer Collaboration
  
• Scripps-Led Consortium that Combines Physics and Oncology Receives $10M
  
• Champions Biotechnology Gains Rights to Ramot’s Preclinical Anticancer Agent
  
• Micromet Obtains $11.84M Up Front in Cancer R&D Deal with Sanofi-Aventis
  
• Astex Signs CRADA with NCI to Investigate Its Small Molecule Therapeutic
  
• ProMetic to Provide Halozyme with Synthetic Ligand Affinity Adsorbent
  
• Boehringer Ingelheim Pledges $22.5M to Fund Another Four Years of Partnership with Evotec
  
• Gene Pinpointed that Could Negate Cancer Cells’ Ability to Repair Themselves
  
• Talecris Pours $268.7M into Production Plant in North Carolina
  
• Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology
  
• Oncodesign to Provide Sanofi-Aventis with Exclusive Cancer Models
  
• Lonza Launches Cells on Demand Services for Cell Culture and Transfection